Supraciliary microstenting with phacoemulsification in patients with open-angle glaucoma and cataracts
摘要
Elevated intraocular pressure (IOP) is a major risk factor for the development or progression of glaucoma. Lowering IOP is the only proven therapeutic approach to the management of glaucoma. IOP can be lowered by medication, laser treatment or surgery (1). Generally, instillation of IOP-lowering eye drops remains the first-line treatment because it enables the patients to avoid the potential risk of vision-threatening complications associated with filtering surgery such as blebitis, hypotony maculopathy, and endophthalmitis. However, topical anti-glaucoma treatment also has downsides such as drug-related adverse effects, ocular surface toxicity, and poor adherence. Moreover, medical treatment often fails to reduce IOP sufficiently enough to prevent glaucomatous progression. Despite the risks of complications, surgical treatment is recommended in such cases (2,3).
